Literature DB >> 12009006

c-myc is required for osteoclast differentiation.

R Battaglino1, D Kim, J Fu, B Vaage, X Y Fu, P Stashenko.   

Abstract

The role of the receptor activator of nuclear factor kappaB (NF-kappaB) ligand (RANKL)-a tumor necrosis factor (TNF)-related cytokine-in osteoclast formation has been established clearly. However, the downstream signaling pathways activated by this cytokine remain largely unknown. To identify genes that play a role in osteoclastogenesis, we used RAW 264.7 mouse monocytes as a model system for the differentiation of multinucleated osteoclasts from mononucleated precursors. RAW 264.7 cells were induced with RANKL to form multinucleated giant osteoclast-like cells (OCLs) that expressed a number of osteoclast-specific markers and were able to form resorption pits on both calcium phosphate films and bone slices. This system was used to identify genes that are regulated by RANKL and may play a role in osteoclast differentiation. The proto-oncogene c-myc was strongly up-regulated in RANKL-induced OCLs but was absent in undifferentiated cells. Expression of Myc partners Max and Mad, on the other hand, was constant during OCL differentiation. We expressed a dominant negative Myc in RAW 264.7 cells and were able to block RANKL-induced OCL formation. Northern Blot analysis revealed a delay and a significant reduction in the level of messenger RNA (mRNA) for tartrate-resistant acid phosphatase (TRAP) and cathepsin K. We conclude that c-myc is a downstream target of RANKL and its expression is required for RANKL-induced osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009006     DOI: 10.1359/jbmr.2002.17.5.763

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  26 in total

1.  Cloning and characterization of osteoclast precursors from the RAW264.7 cell line.

Authors:  Bethany L V Cuetara; Tania N Crotti; Anthony J O'Donoghue; Kevin P McHugh
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Jul-Aug       Impact factor: 2.416

2.  Expression analysis of nha-oc/NHA2: a novel gene selectively expressed in osteoclasts.

Authors:  L Pham; P Purcell; L Morse; P Stashenko; R A Battaglino
Journal:  Gene Expr Patterns       Date:  2007-08-14       Impact factor: 1.224

Review 3.  Signaling networks that control the lineage commitment and differentiation of bone cells.

Authors:  Carrie S Soltanoff; Shuying Yang; Wei Chen; Yi-Ping Li
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

Review 4.  Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.

Authors:  Joel Jules; Jason W Ashley; Xu Feng
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

5.  Structural maintenance of chromosome complexes and bone development: the beginning of a wonderful relationship?

Authors:  Miri Cohen-Zinder; Miri Zinder-Cohen; David Karasik; Itay Onn
Journal:  Bonekey Rep       Date:  2013-08-07

6.  Development of cell-based high-throughput assays for the identification of inhibitors of receptor activator of nuclear factor-kappa B signaling.

Authors:  Jason W Ashley; Erin M McCoy; Daniel A Clements; Zhenqi Shi; Taosheng Chen; Xu Feng
Journal:  Assay Drug Dev Technol       Date:  2010-11-04       Impact factor: 1.738

7.  MYC-dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRα.

Authors:  Seyeon Bae; Min Joon Lee; Se Hwan Mun; Eugenia G Giannopoulou; Vladimir Yong-Gonzalez; Justin R Cross; Koichi Murata; Vincent Giguère; Marjolein van der Meulen; Kyung-Hyun Park-Min
Journal:  J Clin Invest       Date:  2017-05-22       Impact factor: 14.808

8.  The many ways of osteoclast activation.

Authors:  Joseph Lorenzo
Journal:  J Clin Invest       Date:  2017-05-22       Impact factor: 14.808

9.  NHA-oc/NHA2: a mitochondrial cation-proton antiporter selectively expressed in osteoclasts.

Authors:  R A Battaglino; L Pham; L R Morse; M Vokes; A Sharma; P R Odgren; M Yang; H Sasaki; P Stashenko
Journal:  Bone       Date:  2007-09-26       Impact factor: 4.398

10.  Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone.

Authors:  L Endo-Munoz; A Cumming; S Sommerville; I Dickinson; N A Saunders
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.